Thoracic Oncology
The sponsor’s clinical research is centered on lung cancer, with interest in distinguishing malignant disease from other clinical presentations where lung cancer is part of the differential diagnosis. This includes individuals being evaluated after low-dose CT screening and patients with incidental CT-scan findings suspicious for cancer.
- Lung cancer detection
- Screening-eligible populations
- Incidental pulmonary findings
Research activity in this area is focused on supporting earlier and more precise identification of disease within routine respiratory and imaging-based pathways.
Non-Invasive Cancer Diagnostics
The funded work emphasizes diagnostic accuracy for a breath-based test intended to help separate individuals with lung cancer from relevant comparison groups. The clinical setting reflects interest in non-invasive approaches that can complement existing diagnostic evaluation.
- Breath biopsy
- Diagnostic differentiation
- Non-invasive testing
This area aligns with translational research aimed at improving how suspected cancer is identified in patients presenting with ambiguous respiratory or imaging findings.
Respiratory Imaging Pathways
Clinical interest extends to patients undergoing CT-based assessment for possible lung cancer, including those with findings that require further diagnostic clarification. The research landscape therefore intersects with radiology-led workup and downstream cancer evaluation.
- Low-dose CT screening
- Suspicious imaging findings
- Diagnostic triage
These studies sit at the interface of imaging, respiratory medicine, and oncology, where test performance is evaluated in real-world clinical presentations.
Translational Biomarker Research
As a Cambridge-based pharmaceutical company, the sponsor’s funded activity reflects a translational focus on biomarkers that can be used in clinical decision-making for suspected thoracic malignancy. The work is directed toward validating a diagnostic tool in patient groups that mirror routine practice.
- Clinical biomarker validation
- Patient stratification
- Thoracic malignancy assessment
The research also involves collaboration across multiple sites in Europe, supporting evaluation across different care settings.
